Does the media refer more to RPRX or BMY?

In the previous week, Bristol Myers Squibb had 8 more articles in the media than Royalty Pharma. MarketBeat recorded 24 mentions for Bristol Myers Squibb and 16 mentions for Royalty Pharma. Bristol Myers Squibb's average media sentiment score of 0.84 beat Royalty Pharma's score of 0.59 indicating that Bristol Myers Squibb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 8 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bristol Myers Squibb 15 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive

Which has higher valuation and earnings, RPRX or ZTS?

Zoetis has higher revenue and earnings than Royalty Pharma. Zoetis is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Royalty Pharma $2.44B 13.63 $770.95M $1.47 39.30 Zoetis $9.47B 3.31 $2.67B $6.03 12.39

Is RPRX or ZTS more profitable?

Royalty Pharma has a net margin of 33.88% compared to Zoetis' net margin of 27.80%. Zoetis' return on equity of 66.85% beat Royalty Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Royalty Pharma 33.88% 29.25% 14.71% Zoetis 27.80% 66.85% 18.79%

Does the media favor RPRX or ZTS?

In the previous week, Zoetis had 25 more articles in the media than Royalty Pharma. MarketBeat recorded 41 mentions for Zoetis and 16 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.59 beat Zoetis' score of 0.50 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 8 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 13 Very Positive mention(s) 3 Positive mention(s) 22 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RPRX or JAZZ?

In the previous week, Royalty Pharma had 13 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 16 mentions for Royalty Pharma and 3 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.50 beat Royalty Pharma's score of 0.59 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 8 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer RPRX or CORT?

In the previous week, Royalty Pharma had 8 more articles in the media than Corcept Therapeutics. MarketBeat recorded 16 mentions for Royalty Pharma and 8 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.28 beat Royalty Pharma's score of 0.59 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 8 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RPRX or SUPN?

In the previous week, Royalty Pharma had 15 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 16 mentions for Royalty Pharma and 1 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.63 beat Royalty Pharma's score of 0.59 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 8 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Royalty Pharma (RPRX) Competitors

$57.77 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$57.33 -0.44 (-0.75%)

As of 07/2/2026 08:00 PM Eastern

Compare

RPRX vs. BMY, ZTS, JAZZ, CORT, and SUPN

Should you buy Royalty Pharma stock or one of its competitors? MarketBeat compares Royalty Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Royalty Pharma include Bristol Myers Squibb (BMY), Zoetis (ZTS), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.

How does Royalty Pharma compare to Bristol Myers Squibb?

Royalty Pharma (NASDAQ:RPRX) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Royalty Pharma has a net margin of 33.88% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	33.88%	29.25%	14.71%
Bristol Myers Squibb	15.01%	64.87%	13.16%

54.3% of Royalty Pharma shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.6%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.3%. Royalty Pharma pays out 63.9% of its earnings in the form of a dividend. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has raised its dividend for 5 consecutive years and Bristol Myers Squibb has raised its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb has higher revenue and earnings than Royalty Pharma. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.44B	13.63	$770.95M	$1.47	39.30
Bristol Myers Squibb	$48.19B	2.46	$7.05B	$3.56	16.31

Royalty Pharma currently has a consensus target price of $53.71, suggesting a potential downside of 7.02%. Bristol Myers Squibb has a consensus target price of $61.31, suggesting a potential upside of 5.62%. Given Bristol Myers Squibb's higher possible upside, analysts clearly believe Bristol Myers Squibb is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

In the previous week, Bristol Myers Squibb had 8 more articles in the media than Royalty Pharma. MarketBeat recorded 24 mentions for Bristol Myers Squibb and 16 mentions for Royalty Pharma. Bristol Myers Squibb's average media sentiment score of 0.84 beat Royalty Pharma's score of 0.59 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	8 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol Myers Squibb	15 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

Royalty Pharma has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

Summary

Bristol Myers Squibb beats Royalty Pharma on 11 of the 19 factors compared between the two stocks.

How does Royalty Pharma compare to Zoetis?

Royalty Pharma (NASDAQ:RPRX) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Royalty Pharma has a net margin of 33.88% compared to Zoetis' net margin of 27.80%. Zoetis' return on equity of 66.85% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	33.88%	29.25%	14.71%
Zoetis	27.80%	66.85%	18.79%

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.6%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.8%. Royalty Pharma pays out 63.9% of its earnings in the form of a dividend. Zoetis pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has increased its dividend for 5 consecutive years and Zoetis has increased its dividend for 14 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Royalty Pharma has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Royalty Pharma presently has a consensus target price of $53.71, indicating a potential downside of 7.02%. Zoetis has a consensus target price of $126.92, indicating a potential upside of 69.83%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Zoetis	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38

Zoetis has higher revenue and earnings than Royalty Pharma. Zoetis is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.44B	13.63	$770.95M	$1.47	39.30
Zoetis	$9.47B	3.31	$2.67B	$6.03	12.39

In the previous week, Zoetis had 25 more articles in the media than Royalty Pharma. MarketBeat recorded 41 mentions for Zoetis and 16 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.59 beat Zoetis' score of 0.50 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	8 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	13 Very Positive mention(s)	3 Positive mention(s)	22 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Zoetis beats Royalty Pharma on 12 of the 18 factors compared between the two stocks.

How does Royalty Pharma compare to Jazz Pharmaceuticals?

Royalty Pharma (NASDAQ:RPRX) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Royalty Pharma has a net margin of 33.88% compared to Jazz Pharmaceuticals' net margin of 0.66%. Royalty Pharma's return on equity of 29.25% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	33.88%	29.25%	14.71%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

54.3% of Royalty Pharma shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Royalty Pharma has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Royalty Pharma presently has a consensus target price of $53.71, indicating a potential downside of 7.02%. Jazz Pharmaceuticals has a consensus target price of $246.06, indicating a potential upside of 1.06%. Given Jazz Pharmaceuticals' higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.84

Royalty Pharma has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.44B	13.63	$770.95M	$1.47	39.30
Jazz Pharmaceuticals	$4.27B	3.58	-$356.15M	-$0.02	N/A

In the previous week, Royalty Pharma had 13 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 16 mentions for Royalty Pharma and 3 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.50 beat Royalty Pharma's score of 0.59 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	8 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Royalty Pharma beats Jazz Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Royalty Pharma compare to Corcept Therapeutics?

Royalty Pharma (NASDAQ:RPRX) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Royalty Pharma has a net margin of 33.88% compared to Corcept Therapeutics' net margin of 6.14%. Royalty Pharma's return on equity of 29.25% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	33.88%	29.25%	14.71%
Corcept Therapeutics	6.14%	7.40%	5.76%

Royalty Pharma has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.44B	13.63	$770.95M	$1.47	39.30
Corcept Therapeutics	$761.41M	12.72	$99.65M	$0.35	257.74

In the previous week, Royalty Pharma had 8 more articles in the media than Corcept Therapeutics. MarketBeat recorded 16 mentions for Royalty Pharma and 8 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.28 beat Royalty Pharma's score of 0.59 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	8 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma currently has a consensus price target of $53.71, indicating a potential downside of 7.02%. Corcept Therapeutics has a consensus price target of $88.83, indicating a potential downside of 1.53%. Given Corcept Therapeutics' higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Royalty Pharma beats Corcept Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Royalty Pharma compare to Supernus Pharmaceuticals?

Royalty Pharma (NASDAQ:RPRX) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

In the previous week, Royalty Pharma had 15 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 16 mentions for Royalty Pharma and 1 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.63 beat Royalty Pharma's score of 0.59 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	8 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.3% of Royalty Pharma shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Royalty Pharma has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.44B	13.63	$770.95M	$1.47	39.30
Supernus Pharmaceuticals	$718.95M	3.88	-$38.55M	-$0.51	N/A

Royalty Pharma has a net margin of 33.88% compared to Supernus Pharmaceuticals' net margin of -3.74%. Royalty Pharma's return on equity of 29.25% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	33.88%	29.25%	14.71%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

Royalty Pharma has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

Royalty Pharma presently has a consensus target price of $53.71, indicating a potential downside of 7.02%. Supernus Pharmaceuticals has a consensus target price of $62.17, indicating a potential upside of 29.38%. Given Supernus Pharmaceuticals' higher probable upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Royalty Pharma beats Supernus Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

Get Royalty Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RPRX vs. The Competition

Export

Metric	Royalty Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$33.27B	$3.78B	$7.16B	$12.48B
Dividend Yield	1.63%	2.16%	2.66%	6.52%
P/E Ratio	39.30	21.61	28.02	24.70
Price / Sales	13.63	340.19	540.37	99.46
Price / Cash	12.09	147.12	49.26	57.09
Price / Book	3.43	8.66	10.96	6.46
Net Income	$770.95M	$23.81M	$3.57B	$337.01M
7 Day Performance	2.74%	3.39%	2.12%	1.69%
1 Month Performance	3.40%	10.81%	5.25%	3.81%
1 Year Performance	59.04%	62.61%	33.29%	23.90%

Royalty Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RPRX Royalty Pharma	4.3013 of 5 stars	$57.77 flat	$53.71 -7.0%	+59.0%	$33.27B	$2.44B	39.30	80	News Coverage Insider Trade Gap Down
BMY Bristol Myers Squibb	4.5937 of 5 stars	$54.66 +1.2%	$61.31 +12.2%	+23.5%	$110.27B	$48.19B	15.35	32,500	Options Volume Analyst Revision Gap Down
ZTS Zoetis	4.9457 of 5 stars	$75.89 -3.6%	$133.92 +76.5%	-53.1%	$33.00B	$9.47B	12.59	14,500	Trending News Analyst Forecast Gap Down
JAZZ Jazz Pharmaceuticals	3.4207 of 5 stars	$225.92 +0.6%	$246.06 +8.9%	+122.5%	$14.11B	$4.27B	N/A	2,890	Positive News
CORT Corcept Therapeutics	2.926 of 5 stars	$79.71 -0.3%	$88.83 +11.4%	+24.2%	$8.58B	$761.41M	227.75	300	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RPRX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Royalty Pharma (RPRX) Competitors

RPRX vs. BMY, ZTS, JAZZ, CORT, and SUPN

How does Royalty Pharma compare to Bristol Myers Squibb?

Summary

How does Royalty Pharma compare to Zoetis?

Summary

How does Royalty Pharma compare to Jazz Pharmaceuticals?

Summary

How does Royalty Pharma compare to Corcept Therapeutics?

Summary

How does Royalty Pharma compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Royalty Pharma (RPRX) Competitors

RPRX vs. BMY, ZTS, JAZZ, CORT, and SUPN

How does Royalty Pharma compare to Bristol Myers Squibb?

Is RPRX or BMY more profitable?

Do institutionals and insiders hold more shares of RPRX or BMY?

Is RPRX or BMY a better dividend stock?

Which has stronger valuation & earnings, RPRX or BMY?

Do analysts recommend RPRX or BMY?

Does the media refer more to RPRX or BMY?

Which has more volatility and risk, RPRX or BMY?

Summary

How does Royalty Pharma compare to Zoetis?

Is RPRX or ZTS more profitable?

Is RPRX or ZTS a better dividend stock?

Which has more risk & volatility, RPRX or ZTS?

Do analysts prefer RPRX or ZTS?

Which has higher valuation and earnings, RPRX or ZTS?

Does the media favor RPRX or ZTS?

Do insiders and institutionals believe in RPRX or ZTS?

Summary

How does Royalty Pharma compare to Jazz Pharmaceuticals?

Is RPRX or JAZZ more profitable?

Do institutionals and insiders have more ownership in RPRX or JAZZ?

Which has more risk and volatility, RPRX or JAZZ?

Do analysts rate RPRX or JAZZ?

Which has preferable earnings & valuation, RPRX or JAZZ?

Does the media prefer RPRX or JAZZ?

Summary

How does Royalty Pharma compare to Corcept Therapeutics?

Is RPRX or CORT more profitable?

Which has more risk & volatility, RPRX or CORT?

Do insiders and institutionals believe in RPRX or CORT?

Which has higher valuation & earnings, RPRX or CORT?

Does the media prefer RPRX or CORT?

Do analysts prefer RPRX or CORT?

Summary

How does Royalty Pharma compare to Supernus Pharmaceuticals?

Does the media refer more to RPRX or SUPN?

Do institutionals and insiders believe in RPRX or SUPN?

Which has higher earnings and valuation, RPRX or SUPN?

Is RPRX or SUPN more profitable?

Which has more volatility and risk, RPRX or SUPN?

Do analysts prefer RPRX or SUPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools